Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study
Background Greece has the highest proportion of smokers in the European Union with 42% of Greeks admitting that they smoke, based on a 2009 survey. This post-hoc analysis of a prospective, observational study evaluated the effectiveness and safety profile of the smoking cessation aid varenicline, as...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Publishing
2012-02-01
|
| Series: | Tobacco Induced Diseases |
| Subjects: | |
| Online Access: | http://www.journalssystem.com/tid/Varenicline-as-a-smoking-cessation-aid-in-a-Greek-population-a-subanalysis-of-an-observational-study,66081,0,2.html |
| _version_ | 1818757658540244992 |
|---|---|
| author | Christina Gratziou Konstantinos I. Gourgoulianis Paraskevi Argyropoulou Pataka Georgia D. Sykara Michael Messig Sunil Raju |
| author_facet | Christina Gratziou Konstantinos I. Gourgoulianis Paraskevi Argyropoulou Pataka Georgia D. Sykara Michael Messig Sunil Raju |
| author_sort | Christina Gratziou |
| collection | DOAJ |
| description | Background
Greece has the highest proportion of smokers in the European Union with 42% of Greeks admitting
that they smoke, based on a 2009 survey. This post-hoc analysis of a prospective, observational study evaluated the
effectiveness and safety profile of the smoking cessation aid varenicline, as well as potential predictors of quit
success in a Greek population.
Methods
Participants were prescribed varenicline according to the recommendations of the European Summary
of Product Characteristics (1 mg twice daily). The 7-day point prevalence of abstinence at Week 12 was determined
based on verbal reporting using a nicotine use inventory. Abstinence was confirmed by carbon monoxide
measurements of exhaled air at the last visit of the study. The safety profile of varenicline was also assessed.
Results
At baseline, the Greek subsample (n = 196) had a mean age of 42.6 years, with 54.6% of them being men.
Participants had a smoking history of 23.5 years and a Fagerström Test for Nicotine Dependence total score of 6.6.
After 12 weeks of varenicline therapy, 70.4% (95% CI, 64.0-76.7) of all participants had quit smoking. This increased
to 86.2% among participants who had taken the study medication for 80% of the planned number of treatment
days. Age was a significant predictor of quit success. The most frequently observed treatment-emergent adverse
event was nausea, occurring in 13.3% of participants.
Conclusions
In this ‘real-world’ observational study, 70.4% of Greek smokers successfully quit smoking after 12
weeks of varenicline therapy, providing support that varenicline is an effective smoking cessation medication.
Further studies with longer follow-up are warranted.
Trial Registration
ClinicalTrials.gov: NCT00669240 |
| first_indexed | 2024-12-18T06:14:26Z |
| format | Article |
| id | doaj.art-b21cd1c954f246bdbd1dbdd6810eaa72 |
| institution | Directory Open Access Journal |
| issn | 1617-9625 |
| language | English |
| last_indexed | 2024-12-18T06:14:26Z |
| publishDate | 2012-02-01 |
| publisher | European Publishing |
| record_format | Article |
| series | Tobacco Induced Diseases |
| spelling | doaj.art-b21cd1c954f246bdbd1dbdd6810eaa722022-12-21T21:18:19ZengEuropean PublishingTobacco Induced Diseases1617-96252012-02-0110February10.1186/1617-9625-10-166081Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational studyChristina Gratziou0Konstantinos I. Gourgoulianis1Paraskevi Argyropoulou Pataka2Georgia D. Sykara3Michael Messig4Sunil Raju5Evgenidio Hospital, Medical School, University of Athens, Athens, GreecePulmonary Department, Medical School, University of Thessaly, Thessaly, GreeceAristotle University of Thessaloniki, Thessaloniki, GreecePfizer, Athens, GreecePfizer Inc, New York, New York, USAPfizer Ltd, Tadworth, Surrey, UKBackground Greece has the highest proportion of smokers in the European Union with 42% of Greeks admitting that they smoke, based on a 2009 survey. This post-hoc analysis of a prospective, observational study evaluated the effectiveness and safety profile of the smoking cessation aid varenicline, as well as potential predictors of quit success in a Greek population. Methods Participants were prescribed varenicline according to the recommendations of the European Summary of Product Characteristics (1 mg twice daily). The 7-day point prevalence of abstinence at Week 12 was determined based on verbal reporting using a nicotine use inventory. Abstinence was confirmed by carbon monoxide measurements of exhaled air at the last visit of the study. The safety profile of varenicline was also assessed. Results At baseline, the Greek subsample (n = 196) had a mean age of 42.6 years, with 54.6% of them being men. Participants had a smoking history of 23.5 years and a Fagerström Test for Nicotine Dependence total score of 6.6. After 12 weeks of varenicline therapy, 70.4% (95% CI, 64.0-76.7) of all participants had quit smoking. This increased to 86.2% among participants who had taken the study medication for 80% of the planned number of treatment days. Age was a significant predictor of quit success. The most frequently observed treatment-emergent adverse event was nausea, occurring in 13.3% of participants. Conclusions In this ‘real-world’ observational study, 70.4% of Greek smokers successfully quit smoking after 12 weeks of varenicline therapy, providing support that varenicline is an effective smoking cessation medication. Further studies with longer follow-up are warranted. Trial Registration ClinicalTrials.gov: NCT00669240http://www.journalssystem.com/tid/Varenicline-as-a-smoking-cessation-aid-in-a-Greek-population-a-subanalysis-of-an-observational-study,66081,0,2.htmlsmoking cessationGreecevareniclinereal worldobservational |
| spellingShingle | Christina Gratziou Konstantinos I. Gourgoulianis Paraskevi Argyropoulou Pataka Georgia D. Sykara Michael Messig Sunil Raju Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study Tobacco Induced Diseases smoking cessation Greece varenicline real world observational |
| title | Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study |
| title_full | Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study |
| title_fullStr | Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study |
| title_full_unstemmed | Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study |
| title_short | Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study |
| title_sort | varenicline as a smoking cessation aid in a greek population a subanalysis of an observational study |
| topic | smoking cessation Greece varenicline real world observational |
| url | http://www.journalssystem.com/tid/Varenicline-as-a-smoking-cessation-aid-in-a-Greek-population-a-subanalysis-of-an-observational-study,66081,0,2.html |
| work_keys_str_mv | AT christinagratziou vareniclineasasmokingcessationaidinagreekpopulationasubanalysisofanobservationalstudy AT konstantinosigourgoulianis vareniclineasasmokingcessationaidinagreekpopulationasubanalysisofanobservationalstudy AT paraskeviargyropouloupataka vareniclineasasmokingcessationaidinagreekpopulationasubanalysisofanobservationalstudy AT georgiadsykara vareniclineasasmokingcessationaidinagreekpopulationasubanalysisofanobservationalstudy AT michaelmessig vareniclineasasmokingcessationaidinagreekpopulationasubanalysisofanobservationalstudy AT sunilraju vareniclineasasmokingcessationaidinagreekpopulationasubanalysisofanobservationalstudy |